Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: The prevalence of vitamin D deficiency and vitamin D levels in patients with epilepsy (PWE) were systematically evaluated, and the differences between subgroups were analyzed.
Method: We identified all articles investigating the prevalence of vitamin D deficiency in patients with epilepsy from the database established in March 2024 from PubMed, Web of Science, and Embase. We divided them into anti-seizure medication (ASM) interventions and non-ASM interventions according to whether or not someone used ASM.
Results: A total of 68 articles were included. The prevalence of newly diagnosed epilepsy was 50.2% (95% CI: 38.7-61.7%), and the prevalence after ASM intervention was 47.9% (95% CI: 40-55.9%), including 7,070 patients with epilepsy. Subgroup and meta-regression analyses were performed according to the diagnostic criteria, economic development level, region, age, ASM treatment, and other factors. The results showed that the differences were not significant. In addition, the vitamin D content of epilepsy patients (18.719 ng/mL) was lower than that of healthy people (20.295 ng/mL).
Conclusion: The prevalence of vitamin D deficiency in patients with epilepsy is very high. Still, the related factors have little effect on the high prevalence of vitamin D in epilepsy, and ASM intervention can reduce the vitamin D content in patients with epilepsy. Therefore, it is emphasized that monitoring vitamin D levels is part of the routine management of patients with epilepsy.
Systematic Review Registration: The protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO). (registration number CRD42023493896). https://www.crd.york.ac.uk/PROSPERO/ # myprospero.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11392846 | PMC |
| http://dx.doi.org/10.3389/fnut.2024.1439279 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preliminary Safety Study of a Single-dose Perampanel Drip Infusion in Brain Tumor Patients to Prevent Early Postoperative Seizures: The poSTOP Seizure-1 SF Study.
Neurol Med Chir (Tokyo)
September 2025
Department of Neurosurgery, Institute of Medicine, University of Tsukuba.
Early postoperative seizures, defined as occurring within 7 days after surgery, are a significant complication that occurs following neurosurgical procedures involving cerebral manipulation. As a result, short-term antiseizure medication is typically administered in Japan despite the lack of consensus regarding its prophylactic use. Perampanel hydrate, an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, was recently introduced in an intravenous formulation in Japan, providing new potential for early postoperative seizures prevention during the perioperative period.
View Article and Find Full Text PDFLaser Interstitial Thermal Therapy (LITT) in pediatric neurosurgery: Single center retrospective analysis of 41 consecutive procedures.
Neurochirurgie
September 2025
Necker Hospital, Departments of Pediatric Neurosurgery, Radiology, Pediatric Neurology and Anesthesiology; Reference Center for Rare Epilepsies CRéER, Member of ERN Epicare; APHP, Paris, France; Université de Paris Cité, Paris, France; Institut Imagine, INSERM U1163, Paris, France; Paris Kids Can
Introduction: Laser Interstitial Thermal Therapy under MRI control has emerged as a safe and efficient alternative to microsurgery in epilepsy and neurooncology procedures. Yet it has been used only recently in seldom European centers. Here, we report our 4 years' experience with LITT in children (complications, epileptic and oncologic outcomes).
View Article and Find Full Text PDFCortico-Cortical Evoked Potentials: Automated Localization and Classification of Early and Late Responses.
J Neurosci Methods
September 2025
Department of Electrical and Computer Engineering, University of Alabama at Birmingham, Birmingham, AL, USA.
Background: Cortico-cortical evoked potentials (CCEPs), elicited via single-pulse electrical stimulation, are used to map brain networks. These responses comprise early (N1) and late (N2) components, which reflect direct and indirect cortical connectivity. Reliable identification of these components remains difficult due to substantial variability in amplitude, phase, and timing.
View Article and Find Full Text PDFMulti-voxel pattern analysis of face and word encoding fMRI in people with temporal lobe epilepsy and healthy individuals.
Epilepsy Behav
September 2025
Department of Clinical and Experimental Epilepsy, University College London, London the United Kingdom of Great Britain and Northern Ireland; MRI Unit, Chalfont Centre for Epilepsy, Bucks, the United Kingdom of Great Britain and Northern Ireland. Electronic address:
Memory functional MRI (fMRI) has been used to explore cognitive processing in people with refractory temporal lobe epilepsy (TLE) to predict memory decline after anterior temporal lobe resection (ATLR). Traditional studies employed univariate analysis (UVA), focusing on isolated voxel activity in mesial temporal regions. By contrast, multivariate pattern analysis (MVPA), examines distributed activity patterns , offering deeper insight into neural networks supporting cognitive functions.
View Article and Find Full Text PDFElectrographic seizures on responsive neurostimulation: An early and objective measure of response to cenobamate.
Epilepsy Res
August 2025
University of Colorado School of Medicine, Aurora, CO, USA.
Objectives: Responsive neurostimulation (RNS) electrocorticographic (ECoG) data may have a role in objectively assessing the efficacy of add-on antiseizure medications (ASMs). This retrospective, multicenter, observational, 24-week study is the first to report the effects of cenobamate on RNS-detected events (RDE).
Methods: Patients included adults (≥18 years) with a history of recurrent focal seizures and implanted RNS who initiated adjunctive cenobamate ≥ 3 months after RNS implant between 4/1/20-12/15/23 and who received ≥ 2 weeks of cenobamate (≥50 mg/day).